Asensus Surgical Inc Stock Price, News & Analysis

Asensus Surgical, Inc. (NYSE American: ASXC) has announced that the Evangelical Hospital Goettingen-Weende in Germany will become its 7th Senhance Hospital. The hospital will lease a Senhance® Surgical System to enhance their laparoscopic program. This system incorporates advanced features like augmented intelligence and 3D visualization, aiming to improve patient outcomes. Asensus is focusing on Performance-Guided Surgery, providing surgeons with tools to optimize surgical procedures.

Asensus Surgical, Inc. (NYSE American: ASXC) will participate in the H. C. Wainwright 24th Annual Global Investment Conference in New York City on September 12, 2022, at 9:30 AM ET. CEO Anthony Fernando and CFO Shameze Rampertab will host a fireside chat, accessible via a live webcast on the company's investor relations page. The conference aims to enhance investor engagement and share insights about Asensus's innovative Performance-Guided Surgery™ and Digital Laparoscopy technologies. A replay of the session will be available for 90 days on their website.

Asensus Surgical, Inc. (ASXC) reported its Q2 2022 results with a revenue of $1.0 million, a slight decrease from $1.1 million in Q2 2021. Operating expenses increased to $18.2 million, leading to a net loss of $19.6 million or $0.08 per share. The company noted a 34% growth in procedures utilizing the Senhance System, totaling over 670 operations, with a 77% increase in the EMEA region. As of June 30, 2022, cash and investments stood at approximately $103.8 million. Asensus aims to enhance its Performance-Guided Surgery capabilities and expand its digital surgery platform.

Asensus Surgical announced the sale of a Senhance Surgical System to their distribution partner for placement in a hospital located in the Commonwealth of Independent States (CIS). This innovative system revolutionizes laparoscopic procedures through its advanced features, including 3mm instruments, haptic feedback, and an AI-powered platform. The company emphasizes that this partnership aims to enhance patient outcomes and surgical capabilities.

Asensus remains committed to transforming surgical practices with state-of-the-art technology and continuous innovation in performance-guided surgery.

Asensus Surgical, Inc. (NYSE American: ASXC) will announce its 2022 second quarter financial and operational results on August 8, 2022, after market close. A conference call to discuss these results is scheduled for 4:30 p.m. ET on the same day. This medical device company is focused on digitizing surgical interfaces to enhance surgical outcomes through its Performance-Guided Surgery™ platform. The Senhance Surgical System, powered by the Intelligent Surgical Unit, combines digital laparoscopy with augmented intelligence to improve surgeon control and reduce variability.

Asensus Surgical announced the installation of a Senhance Surgical System at the University Hospital Tübingen, marking its sixth facility in Germany. The system will enhance gynecological procedures and is part of a research collaboration aimed at collecting data on surgical outcomes. The Senhance platform incorporates advanced features like augmented intelligence, haptic feedback, and the ability to utilize the smallest surgical instruments in robotic surgery. Asensus aims to improve surgical precision and patient outcomes through its Intelligent Surgical Unit technology.

Asensus Surgical, Inc. (NYSE American: ASXC) announced participation in the Society of Robotic and Digital Surgery Conference from June 30 to July 3, 2022, in Florida. The event aims to engage surgeons and hospital administrators to explore innovative technologies for improved surgical outcomes. The Senhance Surgical System, leveraging augmented intelligence and machine learning, continues to see global usage growth. Dr. Amit Trivedi will present on Performance-Guided Surgery using Senhance, emphasizing its impact on bariatrics.

Asensus Surgical, Inc. (NYSE American: ASXC) will participate in the H. C. Wainwright Global Investment Conference in Miami, Florida. The fireside chat will occur on Tuesday, May 24, 2022, at 12:00 pm Eastern Time. Interested parties can access the webcast on the company's investor relations page, with a replay available for 90 days. Asensus Surgical focuses on digitizing the surgical experience with its Senhance® Surgical System and Intelligent Surgical Unit™ (ISU™), aiming to improve surgical outcomes through machine vision and augmented intelligence.

Asensus Surgical, Inc. (ASXC) reported its Q1 2022 results, highlighting a 31% increase in global procedures to over 650. Revenue stood at $1.1 million, down from $2.1 million in Q1 2021. Operating expenses rose to $18.2 million from $14.4 million year-over-year. The company incurred a net loss of $19.1 million or $0.08 per share, compared to $17.3 million or $0.08 per share in the prior year. As of March 31, 2022, cash and investments totaled approximately $118.5 million. The company expects significant advancements in its technology and market presence throughout 2022.